Precision Medicine in Multiple Myeloma

Join us for a captivating discussion with Prof Pieter Sonneveld, MD, PhD, from Erasmus MC Cancer Institute in Rotterdam, the Netherlands, as he explores the evolution of precision medicine in multiple myeloma. 

Prof. Sonneveld outlines the improvements in multiple myeloma treatment over the past decade, describing the progressive addition of targeted therapies such as daratumumab and bispecific antibodies, BiTEs, and CAR-T cells to the therapeutic arsenal. 

Discover how treatment selection now hinges on whether a one-off or continuous therapy is most suitable, acknowledging the challenges of limited availability in Europe due to cost considerations. Learn about the outstanding findings from the phase III PERSEUS trial, demonstrating the effectiveness of daratumumab combined with lenalidomide for newly diagnosed transplant-eligible patients and transforming their standard of care. 

This interview unveils cutting-edge strategies that are reshaping myeloma prognosis and underscores the importance of early adoption of novel therapies for improved patient outcomes.

Host: Isabel Olivera-Martinez, PhD

Guest: Prof Peter Sonneveld

This is the fifth episode in a series of podcasts covering precision medicine across various disorders; more podcasts will be available in the future. Stay tuned!
Learn More

What did you think of this podcast? Share your opinions with us in this short feedback survey.

Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.

Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.